{"id":"acetarsol","rwe":[{"pmid":"30499784","year":"2019","title":"Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience.","finding":"","journal":"European journal of gastroenterology & hepatology","studyType":"Clinical Study"},{"pmid":"29457211","year":"2018","title":"Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease.","finding":"","journal":"Digestive diseases and sciences","studyType":"Clinical Study"},{"pmid":"21495268","year":"2010","title":"Speciation of arsenic in urine following intravenous administration of arsthinol in mice.","finding":"","journal":"European journal of drug metabolism and pharmacokinetics","studyType":"Clinical Study"},{"pmid":"21138457","year":"2011","title":"Review article: the role of non-biological drugs in refractory inflammatory bowel disease.","finding":"","journal":"Alimentary pharmacology & therapeutics","studyType":"Clinical Study"},{"pmid":"16004634","year":"2005","title":"Recalcitrant Trichomonas vaginalis infection--a case series.","finding":"","journal":"International journal of STD & AIDS","studyType":"Clinical Study"}],"tags":[{"label":"acetarsol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A07AX02","category":"atc"},{"label":"Active","category":"status"},{"label":"Amebic infection","category":"indication"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"arsaphen","offLabel":[],"synonyms":["acetarsol","acetarsone","acetphenarsine","arsaphen"],"timeline":[],"brandName":"Arsaphen","ecosystem":[{"indication":"Amebic infection","otherDrugs":[{"name":"diiodohydroxyquinoline","slug":"diiodohydroxyquinoline","company":""},{"name":"sulfacetamide","slug":"sulfacetamide","company":"Ortho Mcneil Pharm"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","drugClass":"acetarsol","explanation":"Imagine your body as a city, and the amebic parasites as unwanted visitors. Arsaphen is like a special kind of police officer that helps keep the city clean by stopping the parasites from multiplying and taking over. By doing so, it helps your body fight off the infection and recover.","oneSentence":"Arsaphen works by inhibiting the growth and reproduction of amebic parasites.","technicalDetail":"Acetarsol, the active ingredient in Arsaphen, is thought to exert its antiparasitic effects by disrupting the cell membrane of amebic parasites, ultimately leading to their death and the resolution of infection."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Acetarsol","title":"Acetarsol","extract":"Acetarsol is an anti-infective drug. It was first discovered in 1921 at Pasteur Institute by Ernest Fourneau, and sold under the brand name Stovarsol. It was available in oral form and also as a suppository. It has been cancelled and withdrawn from the market since August 12, 1997."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/55","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=acetarsol","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=acetarsol","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Acetarsol","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:22:51.320922","biosimilars":[],"competitors":[],"genericName":"acetarsol","indications":{"approved":[{"name":"Amebic infection","source":"DrugCentral","snomedId":111910009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02515656","phase":"PHASE3","title":"Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis","status":"COMPLETED","sponsor":"Laboratoire Innotech International","startDate":"2015-09","conditions":["Vaginitis"],"enrollment":661,"completionDate":"2016-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005948","UNII":"806529YU1N","CHEBI":"CHEBI:135135","INN_ID":"371","UMLSCUI":"C0050436","ChEMBL_ID":"CHEMBL1330792","KEGG_DRUG":"D07110","DRUGBANK_ID":"DB13268","PUBCHEM_CID":"1985","SNOMEDCT_US":"22236007","MESH_SUPPLEMENTAL_RECORD_UI":"C005284"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":30,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"A07AX02","allCodes":["A07AX02","G01AB01","P01CD02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2019 Feb","pmid":"30499784","title":"Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience.","journal":"European journal of gastroenterology & hepatology"},{"date":"2018 Apr","pmid":"29457211","title":"Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease.","journal":"Digestive diseases and sciences"},{"date":"2010 Sep","pmid":"21495268","title":"Speciation of arsenic in urine following intravenous administration of arsthinol in mice.","journal":"European journal of drug metabolism and pharmacokinetics"},{"date":"2011 Feb","pmid":"21138457","title":"Review article: the role of non-biological drugs in refractory inflammatory bowel disease.","journal":"Alimentary pharmacology & therapeutics"},{"date":"2005 Jul","pmid":"16004634","title":"Recalcitrant Trichomonas vaginalis infection--a case series.","journal":"International journal of STD & AIDS"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Arsaphen (acetarsol) is a small molecule drug in the acetarsol class, originally developed by an unknown entity and currently owned by an unknown entity. It is used to treat amebic infections, a condition caused by a type of parasite. The commercial status of Arsaphen is unclear, but it is likely to be a generic medication given the lack of information on patent status. Key safety considerations for Arsaphen are unknown. Further research is needed to fully understand its pharmacokinetics and potential side effects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}